Response to: Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 3, 2006, Pages 394-

  Khanlou, Homayoun ^a   Louie, Stan ^b   Farthing, Charles ^a  

^a AIDS HEALTHCARE FOUNDATION   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; RITONAVIR;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NONHUMAN; PRIORITY JOURNAL;

EID: 33645109097     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000214822.33905.87     Document Type: Letter

References (9)

1. Guiard-Schmid JB, Poirier JM, Bonnard P, et al. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J Acquir Immune Defic Syndr. 2005;41:395.
2. Khanlou H, Farthing C. Co-administration of atazanavir with proton pump inhibitors and H2 blockers. J Acquir Immune Defic Syndr. 2005;39:503.
3. Agarwala S, Gray K, Wang Y, et al. Pharmacokinetic effect of omeprazole on atazanavir with ritonavir in healthy subjects [abstract 658]. Presented at: 12th Conference on Retroviruses and Opportunistic infections; 2005; Boston.
4. Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic effect of famotidine on atazanavir with ritonavir and without ritonavir in healthy subjects [abstract 11]. Presented at: Sixth International Conference on Clinical Pharmacology on HIV Therapy; 2005; Quebec City.
5. Reyataz (atazanavir sulfate) package insert, revised June 2005. Princeton, NJ: Bristol-Myers Squibb Company Available at: www.reyataz.com. Accessed October 15, 2005.
6. trough is associated with efficacy and safety: definition of therapeutic range [abstract 645]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston.
7. Winston A, Bloch M, Carr A, et al. The clinical correlations of trough plasma atazanavir levels in a cohort of HIV-1 positive individuals receiving HAART [abstract 656]. Presented at: 12th Conference on Retroviruses and Opportunistic infections; 2005; Boston.
8. Khanlou H, Bhatti L, Farthing F. Interaction between atazanavir and fos amprenavir in the treatment of HIV-infected patients. J Acquir Immune Defic Syndr. 2005. (In press).
9. Antoniou T, Yoong D, Beique L, et al. Impact of acid-suppressive therapy on virologie response to atazanavir-based regimen in antiretroviral experienced patients: a case series. J Acquir Immune Defic Syndr. 2005;39:126-128.